Global Fusion Biopsy Market to Reach $803.5 Million by 2035 as AI Adoption Lifts Growth
Updated
Updated · BioSpace · May 12
Global Fusion Biopsy Market to Reach $803.5 Million by 2035 as AI Adoption Lifts Growth
1 articles · Updated · BioSpace · May 12
$803.5 million is the projected size of the global fusion biopsy market by 2035, up from $383.5 million in 2026, implying an 8.6% CAGR.
Rising prostate cancer cases and wider use of AI-powered MRI-ultrasound fusion systems are driving demand for more accurate, minimally invasive targeted biopsies over traditional random sampling.
North America held 41% of the market in 2025, while Asia-Pacific is forecast to post the fastest growth as healthcare investment and early-diagnosis awareness increase.
Software is expected to be the fastest-growing product segment, and transperineal biopsy is gaining traction because it lowers infection risk and can improve targeting accuracy.
High equipment costs, specialist training needs, limited MRI access and uneven reimbursement still threaten adoption, especially in smaller hospitals and lower-income regions.
Can North America's med-tech dominance withstand Asia's rapid rise in AI-driven cancer diagnostics?
As new rules favor outpatient centers, will hospitals lose the race for precision cancer diagnostics?
Is AI-powered cancer diagnosis creating a new healthcare divide between the rich and poor?
Global Fusion Biopsy Market to Reach $1.21 Billion by 2030: AI Integration Drives Precision in Prostate Cancer Diagnostics
Overview
The global fusion biopsy market is experiencing strong growth, with estimates placing its size at around USD 736.6 million to USD 750 million in 2024 and reaching USD 0.82 billion in 2025. Despite some variation in projections, experts agree the market will expand significantly over the next decade, driven by rising prostate cancer cases and the adoption of advanced technologies like AI-powered MRI-ultrasound fusion. Forecasts suggest a compound annual growth rate of around 8%, highlighting the increasing demand for precise, minimally invasive diagnostic tools and the transformative impact of artificial intelligence on biopsy accuracy and efficiency.